Printer Friendly

STERLING WINTHROP AND SANOFI PHARMA ANNOUNCE OPERATIONS NOW UNDERWAY IN FOURTEEN MAJOR COUNTRIES; PROGRESS REPORTED IN R&D

 STERLING WINTHROP AND SANOFI PHARMA ANNOUNCE OPERATIONS NOW UNDERWAY
 IN FOURTEEN MAJOR COUNTRIES; PROGRESS REPORTED IN R&D
 NEW YORK, Jan. 24 /PRNewswire/ -- Sterling Winthrop Inc. and Sanofi Pharma, which last year announced the initiation of joint alliance operations in the United States, France and Germany, today announced the initiation of joint operations in 11 additional countries. These "country closings" reflect the continuing implementation of an innovative alliance agreed to by the two companies in January 1991.
 New pharmaceutical products alliance organizations are now operational under the name Sanofi Winthrop in Belgium, Canada, England, Holland, the Irish Republic, Italy, Portugal, Spain and Switzerland, in addition to the United States, France and Germany, and are soon to be operational in Brazil and Mexico. New York-based Sterling Winthrop manages the operations in the United States, Brazil, Canada and Mexico. Sanofi Pharma manages the pharmaceutical operations in the ten European countries.
 A regional European consumer health products alliance is also operational in France, Germany, Belgium, England, Holland, the Irish Republic, Italy, Portugal and Switzerland under the name Sterling Health, except in France and Italy where the alliance is operating as Sterling Midy. The European consumer health products alliance in all countries is managed by Sterling Winthrop.
 "We continue to make great progress in implementing our global alliance," said Louis P. Mattis, chairman, president and chief executive officer of Sterling Winthrop. "The initiation of operations in eleven additional countries is indicative of our two companies' dedication to achieving our shared vision."
 In addition to the implementation of operations in a number of major countries, the Sterling Winthrop and Sanofi Pharma alliance has led to decisions to co-finance clinical development of six pharmaceutical compounds in the areas of thrombosis, cardiovascular disease and diagnostic imaging.
 Sterling Winthrop and Sanofi Pharma Alliance
 As a result of the alliance, Sterling Winthrop and Sanofi Pharma will rank among the top 20 pharmaceutical groupings worldwide, with annual sales of more than $2 billion. The alliance will be among the leaders in pharmaceutical R&D, with aggregate combined expenditures of approximately $500 million, supported by more than 3,200 scientific and support personnel. Sterling Health, the consumer health products alliance operation, will rank number one in Europe.
 The Sterling Winthrop and Sanofi Pharma alliance benefits from the geographic complementarity of the two companies, their similar research orientation and their common vision. The alliance is well positioned to meet the challenges in the next decade, and to rapidly introduce innovative and improved products.
 Alliance Vision
 Together, Sterling Winthrop Inc., headquartered in New York City, and Sanofi Pharma, headquartered in Paris, France, have developed a common vision for the alliance which states: "Together, we are a worldwide team committed to creating distinctive solutions for the needs of mankind in pharmaceutical and consumer health products."
 -0- 1/24/92
 /CONTACT: Terry G. Kelley, 212-907-3009, or Carol J. Perlman, 212-907-2724, both of Sterling Winthrop/ CO: Sterling Winthrop Inc.; Sanofi Pharma ST: New York IN: MTC SU: JVN


JT -- NY002 -- 3130 01/24/92 08:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 24, 1992
Words:501
Previous Article:U.S. ALCOHOL TESTING OF AMERICA ANNOUNCES STOCK SPLIT
Next Article:PFIZER REPORTS 1991 EARNINGS OF $2.13 PER SHARE, WHICH REFLECTS A $0.58 CHARGE FOR FUTURE SHILEY HEART VALVE FRACTURE CLAIMS
Topics:


Related Articles
STERLING WINTHROP AND SANOFI ANNOUNCE INITIATION OF ALLIANCE OPERATIONS IN GERMANY
STERLING WINTHROP ANNOUNCES SANOFI WINTHROP LICENSING AGREEMENT FOR PREFILLED NEEDLE-FREE SYRINGE WITH BAXTER HEALTHCARE
STERLING WINTHROP AND ELF SANOFI ANNOUNCE CONTINUED PROGRESS IN ALLIANCE; SANOFI WINTHROP PURCHASES MINORITY INTEREST IN CHINOIN
STERLING WINTHROP AND ELF SANOFI ANNOUNCE JOINT OPERATIONS NOW UNDER WAY THROUGHOUT EUROPE WITH ADDITION OF SCANDINAVIAN COUNTRIES
STERLING WINTHROP'S U.S. PHARMACEUTICALS UNIT, SANOFI WINTHROP PHARMACEUTICALS, AND MEDRAD, ANNOUNCE DEVELOPMENT AGREEMENT
KODAK & STERLING WINTHROP DESCRIBE SUCCESSES SINCE ACQUISITION
STERLING WINTHROP NAMES SHOFF V.P., OPERATIONS, PHARMACEUTICALS GROUP; PETERS SUCCEEDS SHOFF AS PRESIDENT, SANOFFI WINTHROP USA
STERLING HEALTH TO MARKET PANADOL AND OTHER CONSUMER MEDICINES IN THE PEOPLE'S REPUBLIC OF CHINA
STERLING WINTHROP INC., ELF SANOFI ALLIANCE AGREES IN PRINCIPLE TO ACQUIRE DAKOTA PHARMA S.A.
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters